Goto Hideki
Department of Hematology, Hokkaido University Hospital.
Rinsho Ketsueki. 2022;63(6):580-588. doi: 10.11406/rinketsu.63.580.
With the advent of new drugs, the treatment outcome of multiple myeloma (MM) has dramatically improved. However, cure for MM has been difficult to attain, and the prognosis of cases resistant to various treatments remains extremely poor. In March 2021, the United States Food and Drug Administration approved idecabtagene vicleucel (Ide-cel) -a B-cell maturation antigen-targeted chimeric antigen receptor (CAR) T-cell therapy -for the treatment of patients with relapsed/refractory MM. The Japanese Ministry of Health, Labor and Welfare approved Ide-cel in December 2021, and CAR T-cell therapy for MM will soon be available for clinical use. This review highlights the latest evidence regarding CAR T-cell therapy for MM.
随着新药的出现，多发性骨髓瘤（MM）的治疗效果有了显著改善。然而，治愈MM一直难以实现，对各种治疗耐药的病例预后仍然极差。2021年3月，美国食品药品监督管理局批准了idecabtagene vicleucel（Ide-cel）——一种靶向B细胞成熟抗原的嵌合抗原受体（CAR）T细胞疗法——用于治疗复发/难治性MM患者。日本厚生劳动省于2021年12月批准了Ide-cel，MM的CAR T细胞疗法很快将可用于临床。本综述重点介绍了关于MM的CAR T细胞疗法的最新证据。
